Biophagy’s anti-viral program with Dr. Bradfute (UNM) is being extended to include zika and hanta viruses
2021 News and Announcements
Biophagy announces the granting of a USPTO composition-of-matter patent for several compounds in its BPY-100 series. These proprietary molecules have shown activity in assays related to tuberculosis, covid-19, and neurodegenerative disorders.
Biophagy initiates a collaboration with Dr. Ramesh Jha, Los Alamos National Laboratories, to study its antiviral compounds using molecular docking. This will help determine ligand affinity and specificity for use in lead development.
Biophagy is awarded a STEP grant through the NM Department of Economic Development for upgrading its website. This will help attract international partners and collaborators.
2020 News and Announcements
Biophagy presents “Potential of Proprietary Molecules for Inducing Autophagy and Enhancing Antibiotic Treatment of Tuberculosis” at the Keystone Symposium, Tuberculosis: Immunity and Immune Evasion,” Santa Fe, NM
Biophagy institutes a new division, CellWatch™, to develop its over-the-counter/direct-to-consumer products for the stimulation and measurement of autophagy in individuals.
Biophagy announces the addition of Bhaskar Suda, PhD, to its team of consultants. Bhaskar will develop and run autophagy measuring assays and study proprietary compounds in neurodegenerative disorders.
Biophagy initiates a new program to study its proprietary compounds in SARS-CoV-2 (covid-19). These studies will be conducted by Dr. Steven Bradfute at UNM.
Biophagy presents “Examining the Potency of Potential Autophagy Inducing Drugs,” at a UNM Discovery Symposium
2019 News and Announcements
Biophagy is awarded a second NMSBA leverage grant with Sandia National Laboratories to lead a team of three companies (including Avisa Pharma and Omphalos Biosciences) towards identifying a lead autophagy stimulant in tuberculosis. The team will be working with human TB bacteria (M. tuberculosis, attenuated) and human macrophages to determine the effects of autophagy on isoniazid antibiotic enhancement and on U-TAID (proprietary antibiotic). They will also use an siRNA knockdown cell line to delineate the direct role of autophagy in compound activity and antibiotic enhancement.
Biophagy presents “Autophagy: From Model Systems to Therapeutic Opportunities, 2/19/19, Keystone Symposium, Santa Fe, NM.
2018 News and Announcements
Biophagy is awarded a New Mexico Small Business Assistance (NMSBA) leverage grant with Sandia National Laboratories to lead a team of four companies (including Avisa Pharma, PureInfo Discovery, and Omphalos Biosciences) to investigate binding dynamics of several proprietary autophagy stimulants on cytoskeleton and lysosome movement. They will also study compound enhancement of antibiotic killing using M. bovis, in mouse macrophages. This is a surrogate assay for tuberculosis.
Biophagy initiates a collaboration with Dr. Karin High, UNM, to study its proprietary compounds in chronic neuropathic pain, in vivo.
2017 News and Announcements
Biophagy, working with Sandia National Laboratories, is awarded an individual company grant from NMSBA to study the relative potencies and binding sites of several autophagy stimulant combinations.
Biophagy announces the addition of Ian Henderson, PhD, as its head of medicinal chemistry
2016 News and Announcements
Albuquerque Business First awards Dr. Mary Ortner, Biophagy’s CEO, its Woman of Influence award in recognition of her contributions to business development in Albuquerque.
Biophagy opens a second office in Mountainair, NM
Biophagy, working with Sandia National Laboratories, is awarded an individual company grant from NMSBA to study the binding sites and autophagy stimulating activities of several UNM compounds under consideration for licensing.
2015 News and Announcements
Dr. Mary Ortner, is elected president of NMBio.
Biophagy changes its corporate structure from LLC to Inc.
Biophagy, working with Sandia National Laboratories, receives an individual company grant from New Mexico Small Business Assistance (NMSBA) to investigate curcumin and resveratrol analogs for autophagy activity.
2014 News and Announcements
Biophagy, working with Sandia National Laboratories, is awarded a grant from New Mexico Small Business Assistance (NMSBA) to develop spectroscopic assays for measuring autophagy and evaluating autophagy stimulant combinations.
Biophagy enters into a license agreement with the University of New Mexico (STC-UNM) to option multiple UNM curcumin and resveratrol analogs for pharmaceutical development.
2013 News and Announcements
Mary Ortner, PhD, MBA, accepts the position of president and CEO. She was previously SVP, business development and corporate alliances, at BioXcel Corporation.
Biophagy signs an option with STC.UNM to license and develop autophagy-related technologies and molecules created at the University of New Mexico
Dr. Steven Bradfute accepts a consulting position with Biophagy. He will advise the company and conduct assays in immunology and virology.
Dr. Mary Ortner, Biophagy’s CEO, is elected vice president of the NM Biotechnology and Biomedical Association (NMBio), the BIO-affiliated NM trade association for bioscience in New Mexico.
2012 News and Announcements
Biophagy, LLC is founded by Dr. Stuart Rose to develop autophagy drugs for unmet medical needs
The company is headquartered in the new BioScience Center in Albuquerque, NM